Bader Al-Rawahi
Biographic Data
| ID | 7750139 |
|---|---|
| NAME | Bader Al-Rawahi |
| GIVEN NAMES | Bader |
| FAMILY NAME | Al-Rawahi |
| SIGNATURE | AL-RAWAHI B |
| AFFILIATIONS | Ministry of Health |
| VERIFIED | No |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Timely vaccination with valid doses in a high coverage country, Oman
Oman achieves high vaccination coverage; however, a noteworthy number of children receive invalid doses. This highlights the urgent need to educate parents and healthcare providers on timely administration of valid doses. Assessing mild illnesses and promptly administering vaccinations can improve complete vaccination rates with valid doses
Treatment outcomes 12 months after antiretroviral therapy initiation in Oman
We used routinely collected programme data on people living with HIV in Oman who started ART in 2014-2018 to assess retention on ART, viral suppression, attrition (mortality or loss to follow-up [LTFU]) and treatment failure (attrition or HIV viral load of > 1000 copies/mL) 12 months after antiretroviral therapy (ART) initiation. We identified 726 patients; 72% were male. Overall, 12 months retention on ART and viral suppression (intention-to-tre…
Retention in HIV care and factors associated with loss to follow-up in Oman
We conducted a cross-sectional analysis to determine the rate of retention in HIV care and the factors associated with loss to follow-up (LTFU) among Omani adults living with HIV who were linked to care as of 31 December 2019. Patients (n = 1610) were identified from a central national HIV surveillance dataset. The majority (68.3%) of patients were male, and the median age was 39 years (IQR, 31–48 years). A total of 1480 patient (91.9%) were reta…
Predictors of late presentation and advanced HIV disease among people living with HIV in Oman (2000–2019)
This analysis indicates that a significant proportion of new HIV cases in Oman continue to present late. This study identified patient subgroups at greatest risk of late HIV diagnosis such as men and older people. Targeted interventions and greater efforts to scale up HIV testing services in Oman are needed
No prominent works on this page.
Predictors of late presentation and advanced HIV disease among people living with HIV in Oman (2000–2019)
This analysis indicates that a significant proportion of new HIV cases in Oman continue to present late. This study identified patient subgroups at greatest risk of late HIV diagnosis such as men and older people. Targeted interventions and greater efforts to scale up HIV testing services in Oman are needed
Retention in HIV care and factors associated with loss to follow-up in Oman
We conducted a cross-sectional analysis to determine the rate of retention in HIV care and the factors associated with loss to follow-up (LTFU) among Omani adults living with HIV who were linked to care as of 31 December 2019. Patients (n = 1610) were identified from a central national HIV surveillance dataset. The majority (68.3%) of patients were male, and the median age was 39 years (IQR, 31–48 years). A total of 1480 patient (91.9%) were reta…
Treatment outcomes 12 months after antiretroviral therapy initiation in Oman
We used routinely collected programme data on people living with HIV in Oman who started ART in 2014-2018 to assess retention on ART, viral suppression, attrition (mortality or loss to follow-up [LTFU]) and treatment failure (attrition or HIV viral load of > 1000 copies/mL) 12 months after antiretroviral therapy (ART) initiation. We identified 726 patients; 72% were male. Overall, 12 months retention on ART and viral suppression (intention-to-tre…
Timely vaccination with valid doses in a high coverage country, Oman
Oman achieves high vaccination coverage; however, a noteworthy number of children receive invalid doses. This highlights the urgent need to educate parents and healthcare providers on timely administration of valid doses. Assessing mild illnesses and promptly administering vaccinations can improve complete vaccination rates with valid doses
Internal Medicine (4 works) · Medicine (4 works) · Family medicine (3 works) · HIV, Drug Use, Sexual Risk (3 works) · HIV/AIDS Research and Interventions (3 works) · Antiretroviral therapy (2 works) · Antiretroviral treatment (2 works) · Biostatistics (2 works) · Demography (2 works) · Epidemiology (2 works)